Guidelines for depot antipsychotic treatment in schizophrenia

Kane, John M.; Aguglia, Eugenio; Altamura, A.C.; Gutiérrez, José Félix Pérez; Brunello, Nicoletta; Fleischhacker, W. Wolfgang; Gaebel, W.; Gerlach, Jes; Guelfi, Julien-D.; Kissling, Werner; Lapierre, Yvon D.; Lindström, Eva; Mendlewicz, Julien; Racagni, Giorgio; Salvador‐Carulla, Luis; Schooler, Nina R.

doi:10.1016/s0924-977x(97)00045-x

Cited by 310 publications

(205 citation statements)

References 54 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…However, in many countries throughout the world fewer than 20% of individuals with schizophrenia receive depot antipsychotic drugs. In Switzerland, the depot treatment rate of 5% was the lowest compared with other West-European countries (Kane et al, 1998).…”

Section: Introductionmentioning

confidence: 77%

“…Additionally in many cases the attitudes and insight of the family and other relatives of the patient in the treatment of the mental disorder have great influence to patient's adherence. There is still inadequate attention being paid to strategies which can enhance medication acceptance and adherence, including the more extensive use of depot antipsychotic administration (Kane et al, 1998).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Jaeger

Rössler

2010

Psychiatry Research

127

135

View full text Add to dashboard Cite

In many countries fewer than 20% of individuals with schizophrenia receive depot antipsychotic medication. Frequently stated reasons are psychiatrist's, patient's and relative's objections to depot treatment. This is the first study that directly compares the attitudes to depot antipsychotics of psychiatrists, patients and relatives. A semi-structured questionnaire about their attitudes to depot antipsychotics was completed by 255 participants (83 patients diagnosed with schizophrenic disorder, 81 psychiatrists in private practice and 91 relatives, not directly related to the patients). Patients were more negative towards depot injections than psychiatrists and relatives. They particularly fear to be constricted in their autonomy when treated with depot antipsychotics and that injections might be painful. About 67% of all patients in our sample did not receive information about depot antipsychotics by their psychiatrist. Less than 10% of psychiatrists offer depot treatment after a first psychotic episode. Psychiatrists use depot antipsychotics in a conservative way although they attribute positive traits to the method. Patients' negative attitudes might relate to the low level of information. To enhance the use of depot antipsychotics, information practices of psychiatrists should be improved. Patients should be informed about different applications forms already during early stages of the illness.

show abstract

Section: Introductionmentioning

confidence: 77%

Section: Introductionmentioning

confidence: 99%

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Jaeger

Rössler

2010

Psychiatry Research

127

135

View full text Add to dashboard Cite

show abstract

“…Daily doses of antipsychotics, including depot antipsychotics, were converted to approximate chlorpromazine equivalents (CPZeq) using published guidelines [16][17][18]. The study was approved by the Research and Ethics Committees of all the co-ordinating centres.…”

Section: Design and Participantsmentioning

confidence: 99%

Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia

Sim

Fujii

et al. 2004

Brit J Clinical Pharma

132

107

View full text Add to dashboard Cite

AimsPrevious studies of the prescription patterns of psychotropic medications in patients with schizophrenia have highlighted a high rate of antipsychotic polypharmacy, but data in Asia are sparse. This study seeks to examine the prevalence of antipsychotic polypharmacy in patients with schizophrenia and compare the differences between patients receiving one vs. those receiving more than one antipsychotic. MethodsAntipsychotic prescription for a sample of 2399 patients with schizophrenia from six countries and territories was evaluated. Daily doses of antipsychotic medications were converted to standard chlorpromazine equivalents (CPZ). ResultsAntipsychotic polypharmacy was found in 45.7% ( n = 1097) of the patients with wide intercountry variations. Polypharmacy was associated with male gender [odds ratio (OR) 1.24, 95% confidence interval (CI) 1.06, 1.46, P < 0.01], advanced age ( t = -7.81, d.f. = 2396, P < 0.001), psychiatric hospital setting (OR 1.34, 95% CI 1.11, 1.62) as well as higher daily CPZeq doses (411.47 vs. 983.10 CPZeq day -1 , z = -25.94, P < 0.001), anticholinergic use (OR 3.17, 95% CI 2.65, 3.79, P < 0.001) and less use of an atypical antipsychotic drug (OR 0.83, 95% CI 0.71, 0.98, P < 0.05). On multivariate analysis, country, age and duration of illness were significantly associated with antipsychotic polypharmacy. ConclusionThis study highlighted the wide intercountry variations of antipsychotic polypharmacy which are likely to be influenced by a complex combination of clinical, setting, cultural and personal practice factors, requiring more research.

show abstract

“…Both socio-demographic characteristics and service availability may influence service use and related costs (Tibaldi et al 2005). For example, the availability of hospital care in one area may have an influence on hospitalisation and 'relapse' rates of schizophrenia when 'relapse' is related to a pattern of service use (Kane et al 1998). Hence, both direct and indirect costs may be significantly higher in an area with bed availability far above the median, than in another area without non-acute hospital care.…”

Section: The Steps Forwardmentioning

confidence: 99%

Economic context analysis in mental health care. Usability of health financing and cost of illness studies for international comparisons

Salvador‐Carulla¹,

Hernández-Peña

2011

Epidemiol Psychiatr Sci

View full text Add to dashboard Cite

This paper discusses an integrated approach to mental health studies on Financing of Illness (FoI) and health accounting, Cost of Illness (CoI) and Burden of Disease (BoD). In order to expand the mental health policies, the following are suggested: (a) an international consensus on the standard scope, methods to collect and to analyse mental health data, as well as to report comparative information; (b) mathematical models are also to be validated and tested in an integrated approach, (c) a better knowledge transfer between clinicians and knowledge engineers, and between researchers and policy makers to translate economic analysis into practice and health planning.

show abstract

Guidelines for depot antipsychotic treatment in schizophrenia

Cited by 310 publications

References 54 publications

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia

Economic context analysis in mental health care. Usability of health financing and cost of illness studies for international comparisons

Contact Info

Product

Resources

About